[go: up one dir, main page]

FR2934955B1 - Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions - Google Patents

Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions

Info

Publication number
FR2934955B1
FR2934955B1 FR0855589A FR0855589A FR2934955B1 FR 2934955 B1 FR2934955 B1 FR 2934955B1 FR 0855589 A FR0855589 A FR 0855589A FR 0855589 A FR0855589 A FR 0855589A FR 2934955 B1 FR2934955 B1 FR 2934955B1
Authority
FR
France
Prior art keywords
nanoemulsions
lipophilic
encapsulation
therapeutic agents
amphiphilic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0855589A
Other languages
English (en)
Other versions
FR2934955A1 (fr
Inventor
Robert Veronique Mourier
Jerome Bibette
Mathieu Goutayer
Y Garcia Fabrice Navarro
Nogues Isabelle Texier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0855589A priority Critical patent/FR2934955B1/fr
Application filed by Commissariat a lEnergie Atomique CEA filed Critical Commissariat a lEnergie Atomique CEA
Priority to CN200980138629.XA priority patent/CN102170866B/zh
Priority to EP09781842.1A priority patent/EP2328554B1/fr
Priority to JP2011522520A priority patent/JP5981139B2/ja
Priority to EP18153452.0A priority patent/EP3335698A1/fr
Priority to ES09781842.1T priority patent/ES2671047T3/es
Priority to US13/058,850 priority patent/US10092506B2/en
Priority to PCT/EP2009/060539 priority patent/WO2010018223A1/fr
Priority to CA2733963A priority patent/CA2733963C/fr
Publication of FR2934955A1 publication Critical patent/FR2934955A1/fr
Application granted granted Critical
Publication of FR2934955B1 publication Critical patent/FR2934955B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0855589A 2008-08-14 2008-08-14 Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions Active FR2934955B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR0855589A FR2934955B1 (fr) 2008-08-14 2008-08-14 Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions
EP09781842.1A EP2328554B1 (fr) 2008-08-14 2009-08-14 Encapsulation d'agents photosensibilisateurs dans des nanoémulsions
JP2011522520A JP5981139B2 (ja) 2008-08-14 2009-08-14 親油性または両親媒性治療薬のナノエマルションへの封入
EP18153452.0A EP3335698A1 (fr) 2008-08-14 2009-08-14 Encapsulation d'agents thérapeutiques lipophiles ou amphiphiles dans des nanoémulsions
CN200980138629.XA CN102170866B (zh) 2008-08-14 2009-08-14 亲脂性或两亲性治疗剂在纳米乳剂中的包囊
ES09781842.1T ES2671047T3 (es) 2008-08-14 2009-08-14 Encapsulado de fotosensibilizadores en nanoemulsiones
US13/058,850 US10092506B2 (en) 2008-08-14 2009-08-14 Encapsulation of lipophilic or amphiphilic therapeutic agents in nano-emulsion
PCT/EP2009/060539 WO2010018223A1 (fr) 2008-08-14 2009-08-14 Encapsulation d'agents thérapeutiques lipophiles ou amphiphiles dans des nanoémulsions
CA2733963A CA2733963C (fr) 2008-08-14 2009-08-14 Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0855589A FR2934955B1 (fr) 2008-08-14 2008-08-14 Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions

Publications (2)

Publication Number Publication Date
FR2934955A1 FR2934955A1 (fr) 2010-02-19
FR2934955B1 true FR2934955B1 (fr) 2011-07-08

Family

ID=40459260

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0855589A Active FR2934955B1 (fr) 2008-08-14 2008-08-14 Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions

Country Status (8)

Country Link
US (1) US10092506B2 (fr)
EP (2) EP3335698A1 (fr)
JP (1) JP5981139B2 (fr)
CN (1) CN102170866B (fr)
CA (1) CA2733963C (fr)
ES (1) ES2671047T3 (fr)
FR (1) FR2934955B1 (fr)
WO (1) WO2010018223A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2934953B1 (fr) 2008-08-14 2011-01-21 Commissariat Energie Atomique Nanoemulsions de nanocristaux
FR2934954B1 (fr) 2008-08-14 2011-07-22 Commissariat Energie Atomique Emulsion fluorescente de vert d'indocyanine
WO2012075534A1 (fr) 2010-12-10 2012-06-14 Ns Technologies Pty Ltd Procédés de formation de miniémulsions et utilisation associée pour l'administration d'agents bioactifs
WO2013008083A1 (fr) * 2011-07-13 2013-01-17 National Institute Of Pharmaceutical Education And Research (Niper) Composition pharmaceutique pouvant améliorer l'efficacité anticancéreuse du tamoxifène
FR2980972B1 (fr) 2011-10-05 2014-02-28 Commissariat Energie Atomique Formulations pour le diagnostic et le traitement de cancers hormonodependants et de cancers des organes de synthese d'hormones steroidiennes.
DE102011116069A1 (de) * 2011-10-18 2013-04-18 Dr. Rimpler Gmbh Lipidnanopartikeldispersion, Verfahren zu deren Herstellung sowie ihre Verwendung
WO2013138520A1 (fr) * 2012-03-13 2013-09-19 University Of Tennessee Research Foundation Composition et système d'administration transdermique
FR2988608B1 (fr) * 2012-03-30 2014-09-05 Commissariat Energie Atomique Materiau, son procede de preparation et ses utilisations
FR2988609B1 (fr) * 2012-03-30 2015-09-04 Commissariat Energie Atomique Formulation pour l'hormonotherapie
FR2991196B1 (fr) * 2012-05-29 2014-06-27 Capsum Nanoparticules ciblantes pour une application biologique
US10253315B2 (en) 2012-08-30 2019-04-09 Commissariat A L'energie Atomique Et Aux Energies Alternatives Method for transfection of nucleic acids into eukaryotic cells in 3D scaffold
FR2994849B1 (fr) 2012-08-30 2015-01-02 Commissariat Energie Atomique Formulation pour la delivrance de sequences nucleotidiques susceptibles de moduler des mecanismes endogenes d'arn interferents
FR2998899B1 (fr) 2012-11-30 2015-07-17 Commissariat Energie Atomique Methode de criblage a haut-debit pour l'identification de biomarqueurs, cibles therapeutiques ou d'agents therapeutiques
US9968673B2 (en) * 2013-02-26 2018-05-15 Commissariat á l'ènergie atomique et aux ènergies alternatives Immunogenic composition in emulsion form comprising two dispersed phases, one comprising an antigen and the other comprising an immunostimulating agent
FR3002454B1 (fr) * 2013-02-26 2015-04-10 Commissariat Energie Atomique Composition immunogene sous forme d'emulsion
WO2015123631A1 (fr) * 2014-02-14 2015-08-20 Jingjun Huang Compositions de systèmes de distribution de nano-émulsion
US11400048B2 (en) * 2014-06-25 2022-08-02 Synergia Bio Sciences Private Limited Pharmaceutical oil-in-water nano-emulsion
EP3103482A1 (fr) 2015-06-11 2016-12-14 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Matériau comprenant du collagène dont les fibres sont revêtues de nanoparticules
EP3103485A1 (fr) 2015-06-11 2016-12-14 Commissariat A L'energie Atomique Et Aux Energies Alternatives Matériau comprenant un polymère susceptible de former un hydrogel et des nanoparticules
FR3043558B1 (fr) * 2015-11-18 2017-12-29 Commissariat Energie Atomique Composition immunogene sous forme d'emulsion comprenant deux phases dispersees, l'une comprenant un antigene et l'autre comprenant un agent immunostimulant
WO2017085248A1 (fr) * 2015-11-18 2017-05-26 Commissariat à l'énergie atomique et aux énergies alternatives Composition immunogène sous forme d'émulsion comprenant deux phases dispersées, l'une comprenant un antigène et l'autre comprenant un agent immunostimulant
EP3225112B1 (fr) * 2016-04-01 2021-08-18 TriOptoTec GmbH Dispersion de photosensibilisant et son utilisation
KR101901986B1 (ko) 2016-11-18 2018-09-27 서울대학교산학협력단 암세포의 선택적 형광 표지를 위한 나노전달체 및 그 제조방법
CN113727768B (zh) * 2018-11-27 2023-05-12 阿维尼翁大学 提取感兴趣的物质的方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78929A0 (en) 1985-07-29 1986-09-30 Abbott Lab Microemulsion compositions for parenteral administration
US4906100A (en) 1988-05-13 1990-03-06 University Of Cincinnati Method of detecting adriamycin (doxorubicin) or daunomycin in the environment
DE68909057T2 (de) 1988-12-20 1994-03-24 Medicontrol Corp Durch hitze dehydratisierte emulsionen.
CH677886A5 (fr) 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
JP2785981B2 (ja) 1989-11-20 1998-08-13 株式会社資生堂 乳化組成物
GB2251381B (en) 1990-07-19 1995-01-25 Charwell Pharma Emulsified fluorescein diester diagnostic compositions
US5403575A (en) 1991-12-12 1995-04-04 Hemagen/Pfc Highly fluorinated, chloro-substituted organic compound-containing emulsions and methods of using them
FR2685636B1 (fr) * 1991-12-31 1995-03-24 Gattefosse Ets Sa Excipient pour suppositoire constitue par une microemulsion et procede pour le fabriquer.
IL101007A (en) 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
IL101387A (en) 1992-03-26 1999-11-30 Pharmos Ltd Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
US5464696A (en) 1992-08-13 1995-11-07 Bracco International B.V. Particles for NMR imaging
JPH08506081A (ja) 1993-02-12 1996-07-02 ファーモス コーポレイション サブミクロン・エマルジョンの調製のための乾燥組成物
CA2091152C (fr) 1993-03-05 2005-05-03 Kirsten Westesen Particules lipidiques solides, particules d'agents bioactifs, et methode de preparation et d'utilisation
US6113921A (en) 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
FR2721210B1 (fr) 1994-06-17 1996-08-02 Oreal Composition de nettoyage contenant des grains lipidiques.
US6540981B2 (en) 1997-12-04 2003-04-01 Amersham Health As Light imaging contrast agents
EP0979107A1 (fr) 1997-04-29 2000-02-16 Nycomed Imaging As Agents de contraste utilises dans des techniques d'imagerie basees sur la lumiere
ATE257014T1 (de) 1997-04-29 2004-01-15 Amersham Health As Lichtbilderzeugungskontrastmitteln
GB9712525D0 (en) 1997-06-16 1997-08-20 Nycomed Imaging As Method
GB9721746D0 (en) 1997-10-15 1997-12-10 Panos Therapeutics Limited Compositions
US5976502A (en) 1997-10-21 1999-11-02 Gholam A. Peyman Method of visualizing particles and blood cells containing a fluorescent lipophilic dye in the retina and choroid of the eye
US6123923A (en) 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
TW537894B (en) 1998-05-26 2003-06-21 Novartis Ag A spontaneously dispersible pharmaceutical composition comprising a piperidine substance P antagonist
DE19852245A1 (de) * 1998-11-12 2000-05-18 Asat Ag Applied Science & Tech 5-Aminolävulinsäure-Nanoemulsion
FR2787326B1 (fr) 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788007B1 (fr) 1999-01-05 2001-02-09 Oreal Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
US20020102301A1 (en) 2000-01-13 2002-08-01 Joseph Schwarz Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
FR2805761B1 (fr) * 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
WO2003045357A1 (fr) 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Formules pharmaceutiques orales contenant du paclitaxel et des derives, et methodes d'administration de celles-ci
WO2005014051A1 (fr) * 2003-08-08 2005-02-17 Barnes-Jewish Hospital Particules d'emulsion destinees a l'imagerie et a la therapie et procedes d'utilisation de celles-ci
FR2860717B1 (fr) 2003-10-13 2006-02-03 Ethypharm Sa Compositions de particules lipidiques solides monodisperses
FR2861986B1 (fr) 2003-11-07 2007-12-14 Oreal Composition de maquillage comprenant une emulsion
EP1563851A1 (fr) 2004-02-17 2005-08-17 Yissum Research Development Company of the Hebrew University of Jerusalem Emulsions cationiques ciblées avec des anticorps pour la livraison de drogues
CN1676125A (zh) 2004-03-31 2005-10-05 张昊 含有紫杉碱类或难溶药物的纳米级乳剂
US20050255044A1 (en) 2004-05-14 2005-11-17 Lomnes Stephen J Contrast agent for combined modality imaging and methods and systems thereof
US8557861B2 (en) 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
ITMI20050218A1 (it) 2005-02-15 2006-08-16 Maycos Italiana Di Comini Miro Nanoemulsioni comprendenti lipoamminoacidi monogliceridi digliceridi poligliceridi degli acidi grassi
DE602005004114T3 (de) 2005-02-18 2016-10-27 Gnosis S.P.A. Verfahren zur Herstellung von Hefe-Mikrokapseln
US20060222716A1 (en) 2005-04-01 2006-10-05 Joseph Schwarz Colloidal solid lipid vehicle for pharmaceutical use
US20060257493A1 (en) * 2005-04-28 2006-11-16 Amiji Mansoor M Nanoparticulate delivery systems for treating multi-drug resistance
US20070148194A1 (en) 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
WO2008042841A2 (fr) * 2006-10-02 2008-04-10 Dr. Reddy's Laboratories Limited Compositions du docétaxel
WO2008102065A1 (fr) 2007-02-14 2008-08-28 Commissariat A L'energie Atomique Emulsions fluorescentes pour l'imagerie optique
EP1985298A1 (fr) * 2007-04-24 2008-10-29 Azad Pharma AG Émulsions ophtalmiques eau dans l'huile contenant des prostaglandines
KR101469026B1 (ko) * 2007-12-11 2014-12-05 삼성디스플레이 주식회사 표시 장치 및 그 표시판의 제조 방법
FR2935001B1 (fr) 2008-08-14 2011-12-30 Commissariat Energie Atomique Emulsion fluorescente
FR2934954B1 (fr) * 2008-08-14 2011-07-22 Commissariat Energie Atomique Emulsion fluorescente de vert d'indocyanine
FR2934953B1 (fr) 2008-08-14 2011-01-21 Commissariat Energie Atomique Nanoemulsions de nanocristaux

Also Published As

Publication number Publication date
EP3335698A1 (fr) 2018-06-20
EP2328554A1 (fr) 2011-06-08
US10092506B2 (en) 2018-10-09
ES2671047T3 (es) 2018-06-04
CA2733963A1 (fr) 2010-02-18
CN102170866B (zh) 2014-09-17
JP5981139B2 (ja) 2016-08-31
US20110201695A1 (en) 2011-08-18
WO2010018223A1 (fr) 2010-02-18
EP2328554B1 (fr) 2018-03-14
JP2012504107A (ja) 2012-02-16
CA2733963C (fr) 2017-02-21
CN102170866A (zh) 2011-08-31
FR2934955A1 (fr) 2010-02-19

Similar Documents

Publication Publication Date Title
FR2934955B1 (fr) Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions
WO2010018216A3 (fr) Émulsion fluorescente de vert d'indocyanine
AR060163A1 (es) Micelas de proteina de suero
EP2093237A4 (fr) Agent anticancéreux comprenant un anticorps anti-hb-egf en tant qu'ingrédient actif
EE200300109A (et) Protsess vedela emulsioonkompositsiooni valmistamiseks ja emulsiooni kontsentraadi valmistamiseks, farmatseutiline kompositsioon, emulsiooni kontsentraat, komplekt ja emulsioonkompositsioon
MXPA05002814A (es) Formulacion para agentes lipofilicos.
TW200613004A (en) External preparation of solid/oil type
TW200637592A (en) Alcohol-free microemulsion composition
SI1742659T1 (sl) Mikrofluidizirane emulzije olja v vodi in sestavki cepiv
FR2892923B1 (fr) Utilisatiion des derives de l'acide para-coumarique ou para- hydroxycinnamique dans des compositions cosmetiques ou dermatologiques.
FR2900052B1 (fr) Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
CL2008000565A1 (es) Concentrado envasado para preparar un consome, caldo, sopa, salsa o para su uso como condimento que comprende 20 a 80% en peso de agua, 1 a 4% de un agente gelante que contiene goma xantano y goma guar, 15 a 40% de sal y 0,5 a 60% de componentes que
RS20090096A (sr) Formulacije pickering emulzije
WO2008104717A3 (fr) Procédé de préparation de nano-émulsions
EP2171095A4 (fr) Micelles mixtes renfermant des conjugués amphiphatiques d'agents arn et leurs utilisations
FR2961814B1 (fr) Nouveaux peptides activateurs de la sirtuine 6 et composition cosmetique ou pharmaceutiques les comprenant.
ATE500835T1 (de) Entzündungshemmende zusammensetzungen und anwendungsverfahren
WO2008070141A3 (fr) Compositions pour administrer des agents thérapeutiques
HUP0402318A2 (hu) Ciklosporint tartalmazó gyógyászati készítmény és alkalmazása
WO2008145943A3 (fr) Vehicule sous forme d'une emulsion huile-dans-eau notamment destine a une utilisation ophtalmique ou dermocosmetique
CL2009000390A1 (es) Composicion liquida de limpieza que comprende 1-30% en surfactante anionico, hasta 5% en surfactante anfotero, 2% de electrolito, 5% de surfactante monoalcanolamida y entre 50-94,5% de agua; kit; uso.
FR2978661B1 (fr) Composition lipidique pour application cosmetique
MA32626B1 (fr) Composition cosmetique comprenant un extrait d'acanthe et utilisation d'acanthe dans une composition cosmetique capillaire
TR200606903A2 (tr) Dermatolojik formülasyonlar.
WO2009065946A3 (fr) Système pharmaceutique constitué d'une émulsion huile dans l'eau et d'une composition solide

Legal Events

Date Code Title Description
CA Change of address
CD Change of name or company name
PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17